Researchers retrospectively examined 2,360 post-transplant biopsies of 548 liver transplantation recipients. Survival was compared between patients with significant steatosis and those with grades zero to one steatosis. Steatosis was found in 309 patients, including 93 patients who had significant steatosis. Steatohepatitis was diagnosed in 57 patients.
Here are four insights:
1. The prevalence of steatosis increased from 30.3 percent at one-year to 47.6 percent at 10 years after liver transplantation.
2. On analyzing pre-transplant factors and initial immunosuppression, alcohol-induced cirrhosis and high body mass index were associated with the development of significant steatosis.
3. On analyzing post-transplant factors, high BMI, serum triglycerides, alcohol consumption and type 2 diabetes mellitus were associated with significant steatosis.
4. Significant steatosis was not associated with a higher fibrosis stage.
More articles on GI/endoscopy:
FDA approves 1st CRC screening blood test, LifeBond’s GI-related sealant receives CE Mark & more — 7 GI company key notes
Aspirin use may lower risk of bile duct cancer: 3 observations
Nor-ursodeoxycholic acid shows success in treating primary sclerosing cholangitis — 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
